Secukinumab: a potential safe option in psoriasis patients affected by multiple sclerosis?

Int J Dermatol. 2020 Aug;59(8):e308-e309. doi: 10.1111/ijd.14902. Epub 2020 May 2.

Authors

Matteo Megna¹, Claudio Marasca¹, Angelo Ruggiero¹, Elisa Camela¹, Gabriella Fabbrocini¹

Affiliation

¹ Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.

PMID: 32358963
DOI: 10.1111/ijd.14902

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized
Dermatologic Agents* / therapeutic use
Humans
Multiple Sclerosis* / drug therapy
Psoriasis* / drug therapy
Severity of Illness Index
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Dermatologic Agents
secukinumab